Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 %. The incidence of grade 2–3 rectal complications is limited (12–15 %). The incidence of grade 2–3 urinary toxicity is 15–26.9 %. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.
|Name||Interstitial Prostate Brachytherapy|